Marc Semigran

Marc Semigran, MD is a cardiologist with subspecialty expertise in cardiomyopathy, heart failure, and cardiac transplantation. Prior to joining Renovacor, Dr. Semigran was Senior Vice President of Medical Sciences and Chief Medical Officer at MyoKardia (acquired by Bristol Myers Squibb in Nov. 2020). There, he led the early development of mavacamten for the treatment of hypertrophic cardiomyopathy, as well as development of other pipeline agents for the treatment of cardiomyopathy. Prior to joining MyoKardia, Dr. Semigran led the Heart Failure and Cardiac Transplant Program at Massachusetts General Hospital as Section Head and Medical Director. Dr. Semigran was a member of the internal medicine and cardiology staff of Massachusetts General Hospital for more than 25 years and is an associate professor at Harvard Medical School. Dr. Semigran has published numerous peer-reviewed papers, received many research awards, served as a principal investigator in major clinical trials, and served in scientific and medical advisory capacities to companies such as GSK, Medtronic, and Bayer.

Dr. Semigran earned AB, AM and MD degrees from Harvard University. He completed his internal medicine residency and cardiology fellowship training at Massachusetts General Hospital.